Focal Segmental Glomerulosclerosis Market 2021 Global Analysis, Growth, Trends, Size, Share, Opportunities, Regional Outlook With Industry Forecast To 2026

SEATTLE, April 12, 2021, (PHARMIWEB) — Global Focal Segmental Glomerulosclerosis Market – Insights

Focal segmental glomerulosclerosis (FSGS) is a disease characterized by formation of scar tissue in the glomeruli, kidney’s filtering system. No drug is available for the treatment of this rare disease. Symptoms of FSGS include edema, proteinuria, weight gain and high level of cholesterol and proteins in the blood. According to the article in Clinical Journal of American Society of Nephrology, 2017, the prevalence of FSGS is 1.5 times higher in men compared to that in women.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2224

Global Focal Segmental Glomerulosclerosis Market: Drivers

Approval and launch of new drugs for the treatment of FSGS is expected to boost growth of the global focal segmental glomerulosclerosis market over the forecast period. For instance, in 2015, the U.S. Food and Drug Administration (FDA) and European Commission both granted Sparsentan, as orphan drug designation for the treatment of FSGS. Sparsentan combines angiotensin receptor blockade with endothelin receptor blockade. The drug is in Phase III trial, which is expected to complete in December 2022.

Moreover, increasing investment in the treatment and management of rare diseases is also expected to boost growth of market. For instance, according to an annual data report from the U.S. Renal Data System 2017, Medicare invested around US$ 34 billion for people on dialysis with chronic kidney diseases.

Global Focal Segmental Glomerulosclerosis Market: Restraint

High cost of dialysis therapy and lack of awareness among the populace regarding FSGS is expected to hinder growth of the market. For instance, according to an article published in University of Michigan 2017, awareness among patients with FSGS is considerably low when the patients are in primary stage of the disease.

Global Focal Segmental Glomerulosclerosis Market: Regional Analysis

North America is expected to hold dominant position in the global focal segmental glomerulosclerosis market over the forecast period. This is attributed to high prevalence of FSGS and chronic kidney diseases in the region. For instance, according to an annual data report by the U.S. Renal Data System 2017, the overall burden of kidney disease, kidney failure with dialysis, and kidney transplantation is the highest in the U.S.

Partnership and collaboration activities are expected to boost growth of the market in Asia Pacific. For instance, Oraxion Therapeutics, Inc., a subsidiary of Indian company Aten Porus, is undergoing preclinical and efficacy study of the drug, ORX-301, which can be used in the treatment of FSGS. In February 2018, Oraxion Therapeutics, Inc. entered into an Option Agreement with a U.S-based biopharmaceutical company. Under the, agreement, the U.S.-based company gets exclusive rights for further clinical studies and license of ORX-301 in the U.S.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2224

Global Focal Segmental Glomerulosclerosis Market: Competitive Landscape 

Major players operating in the global focal segmental glomerulosclerosis (FSGS) market include, GlaxoSmithKline plc., Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A,  and Teva Pharmaceutical Industries Ltd.

Global Focal Segmental Glomerulosclerosis Market: Key Developments 

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, Pfizer Inc. is undergoing clinical trial for the evaluation of its drug, PF-06730512 in adults with primary FSGS. This drug is currently in Phase II study and is expected to complete in June 2021.

Global Focal Segmental Glomerulosclerosis Market – Taxonomy

By Disease Type

• Primary Focal Segmental Glomerulosclerosis
• Secondary Focal Segmental Glomerulosclerosis

By Drug

• Sparsentan (Phase III)

By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837